A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]

There has been recent media coverage concerning a rare atypical femoral fracture that may be a side effect of denosumab (Prolia), an osteoporosis medication manufactured by Amgen. Osteoporosis Canada’s Scientific […]

As a member of The Health Charities Coalition of Canada (HCCC) our organization, Osteoporosis Canada, is pleased to see federal support for the establishment of the Canadian Drug Agency which […]

BISPHOSPHONATES The most common family of drugs used to treat osteoporosis Bisphosphonates are the most common family of drugs used to treat osteoporosis. They are part of the group of […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

Research Competition The Osteoporosis Research Program provides training awards to support Canadian investigators conducting research that promises to yield new insights into the prevention and treatment of osteoporosis and improving […]

No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]